Testing a chip technology for sickle cell samples
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This trial tests a “biochip” device using samples from people with sickle cell disease. If it works, it may help doctors study sickle cell biology more accurately using patient samples.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 12 years old when you agree to join
- You have a confirmed sickle cell diagnosis, such as HbSS or HbSC, or sickle cell with thalassemia
- You (or your legal representative) can read and sign the consent form, and you can follow the study plan
- You are able to attend visits and complete study steps as required
- There is no other health problem or abnormality that could make the study unsafe or interfere with good results
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment called CS-206 for adolescents with severe sickle cell disease. It aims to see if this treatment can help by making stem cell transplants safer and more effective for people who have not done well with standard care.
This study collects feedback through surveys, interviews, and focus groups from people affected by sickle cell disease. Your input helps the research team improve how genomic and gene-therapy information and needs are understood for patients and caregivers.
This study collects blood samples to learn more about sickle cell-related genetics and biology. You might benefit indirectly by helping researchers understand the condition, even though this is laboratory research rather than a medication trial.
This trial tests an investigational drug called DISC-3405 in people with sickle cell disease (SCD) to see if it is safe and how it affects your body. It may be an option if you have certain SCD complications or lab results.
This early-phase study tests whether a “half-matched” donor bone marrow transplant, with special medicines to calm the immune system before transplant, can improve outcomes for people with sickle cell disease. It may help high-risk patients who have frequent complications and don’t have a fully matched donor.
This trial tests CS-206, an experimental therapy for people with sickle cell disease. It aims to reduce severe complications like pain crises, acute chest syndrome, strokes, and other serious events. You may qualify if you have a specific genetic type of sickle cell disease and have experienced complications despite standard treatments.
Hear when a new Sickle Cell Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.